Table 1.
Comparison of clinical characteristics between patients with and without mortality.
| Baseline characteristics | CKD stage 3 | CKD stage 4 | CKD stage 5 | P value |
|---|---|---|---|---|
| Number | 352 | 50 | 35 | |
| Age (years) | 68 ± 12 | 69 ± 13 | 63 ± 15 | 0.066 |
| Male gender (%) | 51.4% | 52.0% | 51.5% | 0.997 |
| Smoking (%) | 10.8% | 6.0% | 8.6% | 0.547 |
| Diabetes (%) | 32.1% | 52.0% | 57.1% | 0.001 |
| Hypertension (%) | 72.4% | 88.0% | 94.3% | 0.002 |
| Dyslipidemia (%) | 42.2% | 55.0% | 31.0% | 0.128 |
| Stroke/TIA (%) | 7.1% | 4.0% | 20.0% | 0.014 |
| Heart failure (%) | 11.9% | 14.0% | 14.3% | 0.859 |
| Heart rate (min−1) | 69 ± 13 | 69 ± 11 | 74 ± 14 | 0.159 |
| Body mass index | 26.1 ± 4.0 | 26.0 ± 3.9 | 26.4 ± 5.9 | 0.897 |
| CHADS2 score | 1.63 ± 1.15 | 2.00 ± 1.07 | 2.34 ± 1.30 | 0.001 |
| CHA2DS2-VASc score | 2.97 ± 1.59 | 3.46 ± 1.76 | 3.54 ± 1.87 | 0.029 |
| Medication | ||||
| Aspirin | 35.9% | 34.7% | 22.9% | 0.303 |
| β-blockers | 44.7% | 46.0% | 45.7% | 0.981 |
| CCBs | 44.6% | 62.0% | 68.6% | 0.003 |
| ACEIs | 8.2% | 8.0% | 5.7% | 0.871 |
| ARBs | 54.0% | 62.0% | 48.6% | 0.434 |
| Diuretics | 34.2% | 50.0% | 60.0% | 0.002 |
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker, CKD chronic kidney disease, TIA transient ischemic attack.